NO135891B - - Google Patents
Download PDFInfo
- Publication number
- NO135891B NO135891B NO4557/71A NO455771A NO135891B NO 135891 B NO135891 B NO 135891B NO 4557/71 A NO4557/71 A NO 4557/71A NO 455771 A NO455771 A NO 455771A NO 135891 B NO135891 B NO 135891B
- Authority
- NO
- Norway
- Prior art keywords
- tetrodotoxin
- lidocaine
- bupivacaine
- concentration
- injection
- Prior art date
Links
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 claims description 46
- 229950010357 tetrodotoxin Drugs 0.000 claims description 45
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 claims description 45
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 39
- 229960004194 lidocaine Drugs 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 31
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 23
- 229960003150 bupivacaine Drugs 0.000 claims description 22
- 238000002347 injection Methods 0.000 claims description 22
- 239000007924 injection Substances 0.000 claims description 22
- COVOMQKTVSVWBZ-CJCGOCGYSA-N deoxytetrodotoxin Chemical compound O1C(C2(O)CO)(O)OC3C(O)C1[C@@H]1CN=C(N)NC12C3O COVOMQKTVSVWBZ-CJCGOCGYSA-N 0.000 claims description 10
- 239000003589 local anesthetic agent Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 10
- 229930182837 (R)-adrenaline Natural products 0.000 description 10
- 229960005139 epinephrine Drugs 0.000 description 10
- 230000003444 anaesthetic effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- -1 4.5-6.75 Chemical compound 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940072358 xylocaine Drugs 0.000 description 2
- HYKGUEIYMKVUSR-NPULLEENSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C HYKGUEIYMKVUSR-NPULLEENSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010039757 Scrotal pain Diseases 0.000 description 1
- 241000269387 Taricha Species 0.000 description 1
- 241001441729 Tetraodontoidei Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- LLHRMWHYJGLIEV-UHFFFAOYSA-N desoxy Chemical group COC1=CC(CCN)=CC(OC)=C1C LLHRMWHYJGLIEV-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001432 effect on motor function Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 229940106885 marcaine Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10994271A | 1971-01-26 | 1971-01-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO135891B true NO135891B (enExample) | 1977-03-14 |
| NO135891C NO135891C (no) | 1978-05-16 |
Family
ID=22330411
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO4557/71A NO135891C (no) | 1971-01-26 | 1971-12-10 | Fremgangsmaate til fremstilling av en lokalanestetisk virksom injeksjonsopploesning |
| NO4558/71A NO135892C (no) | 1971-01-26 | 1971-12-10 | Fremgangsmaate til fremstilling av en lokalanestetisk virksom injeksjonsopploesning |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO4558/71A NO135892C (no) | 1971-01-26 | 1971-12-10 | Fremgangsmaate til fremstilling av en lokalanestetisk virksom injeksjonsopploesning |
Country Status (18)
| Country | Link |
|---|---|
| AT (2) | AT310938B (enExample) |
| AU (1) | AU465875B2 (enExample) |
| BE (2) | BE776769A (enExample) |
| BR (2) | BR7108429D0 (enExample) |
| CA (2) | CA986012A (enExample) |
| DD (2) | DD96144A5 (enExample) |
| DE (2) | DE2163054C3 (enExample) |
| DK (2) | DK130389B (enExample) |
| ES (2) | ES398108A1 (enExample) |
| FR (2) | FR2123277B1 (enExample) |
| GB (1) | GB1370904A (enExample) |
| HU (2) | HU162185B (enExample) |
| IE (2) | IE35937B1 (enExample) |
| LU (1) | LU64664A1 (enExample) |
| NL (2) | NL7117401A (enExample) |
| NO (2) | NO135891C (enExample) |
| SE (2) | SE391286B (enExample) |
| ZA (2) | ZA718326B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4917894A (en) * | 1988-06-29 | 1990-04-17 | Beecham Inc. | Rapid-onset long-duration oral anesthetic composition |
| US6030974A (en) * | 1997-04-02 | 2000-02-29 | The Regents Of The University Of California | Method of anesthesia |
| WO1998051290A2 (en) * | 1997-05-16 | 1998-11-19 | Children's Medical Center Corporation | Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent |
| RU2277097C1 (ru) * | 2004-12-27 | 2006-05-27 | Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) | Высокомеченный тритием дигидрохлорид [3h]сакситоксина |
| CN101563079B (zh) | 2006-03-27 | 2012-12-05 | 威克斯药业有限公司 | 钠通道阻滞剂在制备治疗由于化疗而产生的神经病理性疼痛的药物中的用途 |
| US8952152B2 (en) | 2009-03-24 | 2015-02-10 | Proteus S.A. | Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof |
| KR20210062693A (ko) | 2013-03-15 | 2021-05-31 | 더 칠드런스 메디칼 센터 코포레이션 | 지속성 국소 마취용 네오삭시톡신 조합 제형 |
-
1971
- 1971-12-07 SE SE7115654A patent/SE391286B/xx unknown
- 1971-12-07 SE SE7115655A patent/SE391127B/xx unknown
- 1971-12-10 NO NO4557/71A patent/NO135891C/no unknown
- 1971-12-10 NO NO4558/71A patent/NO135892C/no unknown
- 1971-12-13 ZA ZA718326A patent/ZA718326B/xx unknown
- 1971-12-13 ZA ZA718327A patent/ZA718327B/xx unknown
- 1971-12-14 DK DK609571AA patent/DK130389B/da unknown
- 1971-12-16 HU HU71AA689A patent/HU162185B/hu unknown
- 1971-12-16 BE BE776769A patent/BE776769A/xx unknown
- 1971-12-16 BE BE776768A patent/BE776768A/xx unknown
- 1971-12-16 HU HUAA688A patent/HU162347B/hu unknown
- 1971-12-17 AT AT1084871A patent/AT310938B/de not_active IP Right Cessation
- 1971-12-17 DD DD159910A patent/DD96144A5/xx unknown
- 1971-12-17 DD DD159688A patent/DD96400A5/xx unknown
- 1971-12-17 FR FR7145542A patent/FR2123277B1/fr not_active Expired
- 1971-12-17 NL NL7117401A patent/NL7117401A/xx unknown
- 1971-12-17 NL NL7117404A patent/NL7117404A/xx not_active Application Discontinuation
- 1971-12-17 DK DK619971A patent/DK131606C/da active
- 1971-12-17 FR FR7145543A patent/FR2123278B1/fr not_active Expired
- 1971-12-17 CA CA130,378A patent/CA986012A/en not_active Expired
- 1971-12-17 AT AT1084971A patent/AT310939B/de not_active IP Right Cessation
- 1971-12-17 CA CA130,377A patent/CA983850A/en not_active Expired
- 1971-12-17 GB GB5865871A patent/GB1370904A/en not_active Expired
- 1971-12-18 DE DE2163054A patent/DE2163054C3/de not_active Expired
- 1971-12-18 ES ES398108A patent/ES398108A1/es not_active Expired
- 1971-12-18 ES ES398109A patent/ES398109A1/es not_active Expired
- 1971-12-18 DE DE19712163055 patent/DE2163055A1/de active Pending
- 1971-12-20 IE IE1611/71A patent/IE35937B1/xx unknown
- 1971-12-20 BR BR8429/71A patent/BR7108429D0/pt unknown
- 1971-12-20 IE IE1610/71A patent/IE35910B1/xx unknown
- 1971-12-20 BR BR8428/71A patent/BR7108428D0/pt unknown
- 1971-12-20 AU AU37100/71A patent/AU465875B2/en not_active Expired
-
1972
- 1972-01-26 LU LU64664D patent/LU64664A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vogt | The effect of lowering the 5‐hydroxytryptamine content of the rat spinal cord on analgesia produced by morphine | |
| DE3218761C2 (enExample) | ||
| DE69012591T2 (de) | Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen. | |
| Holzbauer et al. | The action of chlorpromazine on diencephalic sympathetic activity and on the release of adrenocorticotrophic hormone | |
| Bain et al. | The afferent fibres from the abdomen in the splanchnic nerves | |
| Beck et al. | The physiology of vasodilatation | |
| DE2404416A1 (de) | Neurotropisch wirksames mittel und verfahren zu seiner herstellung | |
| Singh et al. | Antifilarial activity of Mallotus philippensis Lam. on Setaria cervi (Nematoda: Filarioidea) in vitro | |
| NO135891B (enExample) | ||
| Morton et al. | Pharmacology of the neurogenic oedema response to electrical stimulation of the saphenous nerve in the rat | |
| Lockett | Some pharmacological actions of piperidine, pyrrolidine, and of pressor concentrates from dog urine | |
| DE69522702T2 (de) | Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält | |
| HARADA et al. | Effect of Gardneria alkaloids on ganglionic transmission in the rabbit and rat superior cervical ganglia in situ | |
| Horsburgh et al. | Chemical properties and physiological actions of Triturus embryonic toxin | |
| Paton et al. | The ganglion blocking action of procainamide | |
| Payne | The influence of mecamylamine on the action of certain other ganglionic blocking agents | |
| DE68905995T2 (de) | Parenteral anzuwendende 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1h-imidazol-4-yl)-methyl)-piperazin enthaltende zubereitungen. | |
| Singh et al. | Exploration of antifilarial potential and possible mechanism of action of the root extracts of Saxifraga stracheyion on cattle filarial parasite Setaria cervi. | |
| DE69831959T2 (de) | Verwendung von (E)-metanicotinederivate als Analgetika | |
| Singh et al. | A Study on the Mechanism of the Hypotensive Activity of Buddleja asiatica (Newarpati) | |
| CN117100784B (zh) | 一种无针注射用中药组合物及其制备方法 | |
| Haynes et al. | Long duration local anesthesia with lecithin-coated microdroplets of methoxyflurane: studies with human skin | |
| DE2019773A1 (de) | Mittel zur Aktivierung der Fibrinolyse des Blutes | |
| Ellis | The pharmacologic analysis of intestinal stimulants | |
| DE2320858A1 (de) | Heilmittel fuer die behandlung von gestoertem blutkreislauf |